Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04635059 · ClinicalTrials.gov registry record · Phase 2
Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer
A Phase 2 study, sponsored by Medical College of Wisconsin.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT04635059 is a Phase 2 study that was terminated before completion, run by Medical College of Wisconsin. The registered enrollment target is 6 participants.
The verdict
NCT04635059, a Phase 2 study, was terminated before completion, sponsored by Medical College of Wisconsin.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is a single-arm, open-label study using pacritinib for patients with histologically confirmed prostate adenocarcinoma, status post definitive treatment and biochemical recurrence.
Interventions
- DRUG Pacritinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2021-06-01 |
| Est. Completion | 2024-10-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04635059
The ClinicalTrials.gov registry entry for NCT04635059 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pacritinib is the first listed.
NCT04635059 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04635059 about?
NCT04635059 is a clinical study titled "Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer". This is a single-arm, open-label study using pacritinib for patients with histologically confirmed prostate adenocarcinoma, status post definitive treatment and biochemical recurrence.
What is the current status of trial NCT04635059?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2021-06-01. Estimated completion is 2024-10-27.
What interventions are being tested in trial NCT04635059?
The interventions under investigation include: Pacritinib (DRUG).
Who is sponsoring clinical trial NCT04635059?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.